Fujing Zhang

机构：Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital · ORCID：0000-0002-7427-7905

发表论文 25 篇 · 总被引 40 次 · h-index 3

代表论文

• Pathophysiology and therapeutic advances in myeloma bone disease (2022 · Chronic Diseases and Translational Medicine · 被引 12)
• Myc rearrangement redefines the stratification of high‐risk multiple myeloma (2024 · Cancer Medicine · 被引 6)
• Percutaneous vertebroplasty/kyphoplasty contributes to the improved outcome in patients with newly diagnosed multiple myeloma: A single center cohort study (2024 · Journal of bone oncology · 被引 4)
• Impaired acute‐phase humoral immunity is the major factor predicting unfavorable outcomes in multiple myeloma patients with SARS ‐ CoV ‐2 Omicron variants outbreak infection (2024 · International Journal of Cancer · 被引 3)
• Chemokine Receptor 4–Targeted PET/CT With 68Ga-Pentixather Detects More Lesions Than 68Ga-Pentixafor PET/CT in Multiple Myeloma (2024 · Clinical Nuclear Medicine · 被引 3)
• YM155 Exerts Anti-Myeloma Effects Via Myc/BBC3 Signaling Pathway in Vitro (2024 · Blood · 被引 2)